Doug Melton to re­unite with his Sem­ma col­lab­o­ra­tors at Ver­tex to de­vel­op 'cu­ra­tive cell ther­a­pies'

4 years ago
People
Pharma

Spot­light­ing sub­group analy­sis, Ther­a­vance tries to carve out 'nar­row, but crit­i­cal­ly im­por­tan­t' mar­ket for failed ...

4 years ago
R&D

As­traZeneca and Io­n­is claim a PC­SK9 win, but will it mat­ter in a crowd­ed mar­ket?

4 years ago
R&D

Blue­bird joins the lay­off flock to re­al­i­ty as gene ther­a­py biotech sheds staff to save it­self

4 years ago
People
R&D

Covid-19 roundup: Con­gress agrees to $10B spend­ing bill; New preprint shows Gilead­'s Vek­lury is in­ef­fec­tive

4 years ago
Coronavirus

FDA con­venes com­mit­tee of vac­cine ex­perts to con­sid­er a flu-like path for Omi­cron-spe­cif­ic boost­ers

4 years ago
FDA+
Coronavirus

CDER chief calls for ad­di­tion­al bud­get funds as staff de­par­tures spiked last sum­mer

4 years ago
FDA+

AMR Ac­tion Fund looks to tack­le an­timi­cro­bial re­sis­tance with first two in­vest­ments — but does the mon­ey ar­rive too ...

4 years ago
Financing
Pharma

'About as true as say­ing the earth is flat': Alzheimer's ex­pert picks apart Bio­gen's Aduhelm man­u­script

4 years ago
People
R&D

Gilead­'s land­mark CAR-T ap­proval leaves Bris­tol My­ers Squibb scram­bling for sec­ond place

4 years ago
Pharma
Cell/Gene Tx

Pfiz­er, J&J, No­vo, Lil­ly and Sanofi among phar­ma TV ads jam­ming at Gram­my mu­sic awards

4 years ago
Pharma
Marketing

FDA tees up a snap re­view for Dupix­ent as Sanofi, Re­gen­eron hunt 4th ap­proval for megablock­buster

4 years ago
Pharma
FDA+

Af­ter steer­ing made-in-Chi­na CAR-T all the way from ob­scu­ri­ty to ap­proval, Frank Fan re­signs from Leg­end

4 years ago
People
China

Ned Sharp­less steps down as head of the Na­tion­al Can­cer In­sti­tute

4 years ago
People
FDA+

Covid-19 roundup: FDA grants pri­or­i­ty re­view to Roche's Actem­ra; WHO sus­pends UN sup­ply of Co­v­ax­in — re­port

4 years ago
Coronavirus

Run­ning be­hind Bris­tol My­ers and J&J, Bay­er inch­es for­ward in the next-gen blood thin­ner race

4 years ago
R&D

Al­ny­lam's po­ten­tial fourth RNAi ap­proval de­layed three months, but im­pact like­ly to be 'mod­est'

4 years ago
R&D
Pharma

'Rapid' path for Curis' lead leukemia drug hits road­block with par­tial clin­i­cal hold af­ter pa­tient death

4 years ago
R&D
Pharma

The good, the bad and lots of just plain old ug­ly: The Q1 num­bers are in

4 years ago

Sanofi taps out­siders for new board to check its home­work on di­ver­si­ty, eq­ui­ty and in­clu­sion

4 years ago
Pharma
Marketing

Cross-cul­tur­al study finds health tech and ad­ver­tis­ing pop­u­lar with His­pan­ic com­mu­ni­ty, amid gen­er­a­tional shifts

4 years ago
Pharma
Marketing

Chirps, chats and Club­hous­es: First-time biotech founders turn to so­cial me­dia for ad­vice, in­vestors and re­cruit­ment

4 years ago
Startups
In Focus

Bris­tol My­ers touts up­beat da­ta for its block­buster heart drug can­di­date

4 years ago
R&D

FDA cuts off use of GSK's Covid treat­ment in al­most half of the US as BA.2 spreads

4 years ago
Coronavirus
First page Previous page 555556557558559560561 Next page Last page
A service from the Financial Times